Marco Materassi
Boston Children's Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marco Materassi.
Acta Paediatrica | 2012
Anita Ammenti; Luigi Cataldi; Roberto Chimenz; Vassilios Fanos; Angela La Manna; Giuseppina Marra; Marco Materassi; Paolo Pecile; Marco Pennesi; Lorena Pisanello; Felice Sica; Antonella Toffolo; Giovanni Montini
We report the recommendations for the diagnosis, treatment, imaging evaluation and use of antibiotic prophylaxis in children with the first febrile urinary tract infection, aged 2 months to 3 years. They were prepared by a working group of the Italian Society of Pediatric Nephrology after careful review of the available literature and a consensus decision, when clear evidence was not available.
Journal of The American Society of Nephrology | 2015
Sabrina Giglio; Aldesia Provenzano; Benedetta Mazzinghi; Francesca Becherucci; Laura Giunti; Giulia Sansavini; Fiammetta Ravaglia; Rosa Maria Roperto; Silvia Farsetti; Elisa Benetti; Mario Rotondi; Luisa Murer; Elena Lazzeri; Laura Lasagni; Marco Materassi; Paola Romagnani
In children, sporadic nephrotic syndrome can be related to a genetic cause, but to what extent genetic alterations associate with resistance to immunosuppression is unknown. In this study, we designed a custom array for next-generation sequencing analysis of 19 target genes, reported as possible causes of nephrotic syndrome, in a cohort of 31 children affected by sporadic steroid-resistant nephrotic syndrome and 38 patients who exhibited a similar but steroid-sensitive clinical phenotype. Patients who exhibited extrarenal symptoms, had a familial history of the disease or consanguinity, or had a congenital onset were excluded. We identified a genetic cause in 32.3% of the children with steroid-resistant disease but zero of 38 children with steroid-sensitive disease. Genetic alterations also associated with lack of response to immunosuppressive agents in children with steroid-resistant disease (0% of patients with alterations versus 57.9% of patients without alterations responded to immunosuppressive agents), whereas clinical features, age at onset, and pathologic findings were similar in steroid-resistant patients with and without alterations. These results suggest that heterogeneous genetic alterations in children with sporadic forms of nephrotic syndrome associate with resistance to steroids as well as immunosuppressive treatments. In these patients, a comprehensive screening using such an array may, thus, be useful for genetic counseling and may help clinical decision making in a fast and cost-efficient manner.
Journal of The American Society of Nephrology | 2015
Elena Lazzeri; Elisa Ronconi; Maria Lucia Angelotti; Anna Peired; Benedetta Mazzinghi; Francesca Becherucci; Sara Conti; Giulia Sansavini; Alessandro Sisti; Fiammetta Ravaglia; Duccio Lombardi; Aldesia Provenzano; Anna Manonelles; Josep M. Cruzado; Sabrina Giglio; Rosa Maria Roperto; Marco Materassi; Laura Lasagni; Paola Romagnani
The critical role of genetic and epigenetic factors in the pathogenesis of kidney disorders is gradually becoming clear, and the need for disease models that recapitulate human kidney disorders in a personalized manner is paramount. In this study, we describe a method to select and amplify renal progenitor cultures from the urine of patients with kidney disorders. Urine-derived human renal progenitors exhibited phenotype and functional properties identical to those purified from kidney tissue, including the capacity to differentiate into tubular cells and podocytes, as demonstrated by confocal microscopy, Western blot analysis of podocyte-specific proteins, and scanning electron microscopy. Lineage tracing studies performed with conditional transgenic mice, in which podocytes are irreversibly tagged upon tamoxifen treatment (NPHS2.iCreER;mT/mG), that were subjected to doxorubicin nephropathy demonstrated that renal progenitors are the only urinary cell population that can be amplified in long-term culture. To validate the use of these cells for personalized modeling of kidney disorders, renal progenitors were obtained from (1) the urine of children with nephrotic syndrome and carrying potentially pathogenic mutations in genes encoding for podocyte proteins and (2) the urine of children without genetic alterations, as validated by next-generation sequencing. Renal progenitors obtained from patients carrying pathogenic mutations generated podocytes that exhibited an abnormal cytoskeleton structure and functional abnormalities compared with those obtained from patients with proteinuria but without genetic mutations. The results of this study demonstrate that urine-derived patient-specific renal progenitor cultures may be an innovative research tool for modeling of genetic kidney disorders.
Ndt Plus | 2016
Francesca Becherucci; Rosa Maria Roperto; Marco Materassi; Paola Romagnani
Chronic kidney disease (CKD) is a major health problem worldwide. Although relatively uncommon in children, it can be a devastating illness with many long-term consequences. CKD presents unique features in childhood and may be considered, at least in part, as a stand-alone nosologic entity. Moreover, some typical features of paediatric CKD, such as the disease aetiology or cardiovascular complications, will not only influence the childs health, but also have long-term impact on the life of the adult that they will become. In this review we will focus on the unique issues of paediatric CKD, in terms of aetiology, clinical features and treatment. In addition, we will discuss factors related to CKD that start during childhood and require appropriate treatments in order to optimize health outcomes and transition to nephrologist management in adult life.
Kidney International | 2017
Viviana Palazzo; Aldesia Provenzano; Francesca Becherucci; Giulia Sansavini; Benedetta Mazzinghi; Valerio Orlandini; Laura Giunti; Rosa Maria Roperto; Marilena Pantaleo; Rosangela Artuso; Elena Andreucci; Sara Bargiacchi; Giovanna Traficante; Stefano Stagi; Luisa Murer; Elisa Benetti; Francesco Emma; Mario Giordano; Francesca Rivieri; Giacomo Colussi; Silvana Penco; Emanuela Manfredini; Maria Rosa Caruso; Livia Garavelli; Simeone Andrulli; Gianluca Vergine; Nunzia Miglietti; E. Mancini; Cristina Malaventura; Antonio Percesepe
Primary distal renal tubular acidosis is a rare genetic disease. Mutations in SLC4A1, ATP6V0A4, and ATP6V1B1 genes have been described as the cause of the disease, transmitted as either an autosomal dominant or recessive trait. Particular clinical features, such as sensorineural hearing loss, have been mainly described in association with mutations in one gene instead of the others. Nevertheless, the diagnosis of distal renal tubular acidosis is essentially based on clinical and laboratory findings, and the series of patients described so far are usually represented by small cohorts. Therefore, a strict genotype-phenotype correlation is still lacking, and questions about whether clinical and laboratory data should direct the genetic analysis remain open. Here, we applied next-generation sequencing in 89 patients with a clinical diagnosis of distal renal tubular acidosis, analyzing the prevalence of genetic defects in SLC4A1, ATP6V0A4, and ATP6V1B1 genes and the clinical phenotype. A genetic cause was determined in 71.9% of cases. In our group of sporadic cases, clinical features, including sensorineural hearing loss, are not specific indicators of the causal underlying gene. Mutations in the ATP6V0A4 gene are quite as frequent as mutations in ATP6V1B1 in patients with recessive disease. Chronic kidney disease was frequent in patients with a long history of the disease. Thus, our results suggest that when distal renal tubular acidosis is suspected, complete genetic testing could be considered, irrespective of the clinical phenotype of the patient.
Italian Journal of Pediatrics | 2017
Andrea Pasini; Elisa Benetti; Giovanni Conti; Luciana Ghio; Marta Lepore; Laura Massella; Daniela Molino; Licia Peruzzi; Francesco Emma; Carmelo Fede; Antonella Trivelli; Silvio Maringhini; Marco Materassi; Giovanni Messina; Giovanni Montini; Luisa Murer; Carmine Pecoraro; Marco Pennesi
This consensus document is aimed at providing an updated, multidisciplinary overview on the diagnosis and treatment of pediatric nephrotic syndrome (NS) at first presentation. It is the first consensus document of its kind to be produced by all the pediatric nephrology centres in Italy, in line with what is already present in other countries such as France, Germany and the USA. It is based on the current knowledge surrounding the symptomatic and steroid treatment of NS, with a view to providing the basis for a separate consensus document on the treatment of relapses. NS is one of the most common pediatric glomerular diseases, with an incidence of around 2–7 cases per 100000 children per year. Corticosteroids are the mainstay of treatment, but the optimal therapeutic regimen for managing childhood idiopathic NS is still under debate. In Italy, shared treatment guidelines were lacking and, consequently, the choice of steroid regimen was based on the clinical expertise of each individual unit. On the basis of the 2015 Cochrane systematic review, KDIGO Guidelines and more recent data from the literature, this working group, with the contribution of all the pediatric nephrology centres in Italy and on the behalf of the Italian Society of Pediatric Nephrology, has produced a shared steroid protocol that will be useful for National Health System hospitals and pediatricians. Investigations at initial presentation and the principal causes of NS to be screened are suggested. In the early phase of the disease, symptomatic treatment is also important as many severe complications can occur which are either directly related to the pathophysiology of the underlying NS or to the steroid treatment itself. To date, very few studies have been published on the prophylaxis and treatment of these early complications, while recommendations are either lacking or conflicting. This consensus provides indications for the prevention, early recognition and treatment of these complications (management of edema and hypovolemia, therapy and prophylaxis of infections and thromboembolic events). Finally, recommendations about the clinical definition of steroid resistance and its initial diagnostic management, as well as indications for renal biopsy are provided.
Pediatric Nephrology | 2007
Ivana Pela; Daniela Seracini; Maria Alice Donati; Giancarlo Lavoratti; Elisabetta Pasquini; Marco Materassi
Pediatric Nephrology | 2015
Andrea Pasini; Gabriella Aceto; Anita Ammenti; Gianluigi Ardissino; Vitalba Azzolina; Alberto Bettinelli; Elena Cama; Sante Cantatore; Antonella Crisafi; Giovanni Conti; Maria D’Agostino; Alessandra Dozza; Alberto Edefonti; Carmelo Fede; Elena Groppali; Chiara Gualeni; Alessandra Lavacchini; Marta Lepore; Silvio Maringhini; Paola Mariotti; Marco Materassi; Francesca Mencarelli; Giovanni Messina; Amata Negri; Marina Piepoli; Fiammetta Ravaglia; Angela Simoni; Laura Spagnoletta; Giovanni Montini
Pediatric Nephrology | 2015
Stefano Picca; Carlo Dionisi-Vici; Andrea Bartuli; Tommaso De Palo; Francesco Papadia; Giovanni Montini; Marco Materassi; Maria Alice Donati; Enrico Verrina; Maria Cristina Schiaffino; Carmine Pecoraro; Emilia Iaccarino; Enrico Vidal; Alberto Burlina; Francesco Emma
Pediatric Nephrology | 2014
Sabrina Giglio; Aldesia Provenzano; Benedetta Mazzinghi; Francesca Becherucci; Laura Giunti; Giulia Sansavini; Fiammetta Ravaglia; Rm Roperto; S Farsetti; Elisa Benetti; Mario Rotondi; Murer; E Eazzeri; Laura Lasagni; Marco Materassi; Paola Romagnani